نتائج البحث

A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.

• Authors : Mouri A; Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan.; Imai H

Subjects: Nivolumab*/Nivolumab*/Nivolumab*/adverse effects ; Nivolumab*/Nivolumab*/Nivolumab*/administration & dosage ; Ipilimumab*/Ipilimumab*/Ipilimumab*/adverse effects

• Source: Cancer medicine [Cancer Med] 2025 Apr; Vol. 14 (8), pp. e70741.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Organ-Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study.

• Authors : Kim JS; Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.; CHA University School of Medicine, Seongnam, Korea.

Subjects: Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/pathology ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/mortality

• Source: Cancer medicine [Cancer Med] 2025 Jun; Vol. 14 (11), pp. e70997.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.

• Authors : Chae YK; Department of Hematology and Oncology, Northwestern University, Chicago, Illinois, USA.; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Subjects: Nivolumab*/Nivolumab*/Nivolumab*/administration & dosage ; Nivolumab*/Nivolumab*/Nivolumab*/adverse effects ; Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use

• Source: Cancer medicine [Cancer Med] 2025 Apr; Vol. 14 (7), pp. e70724.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.

• Authors : Hoogland AI; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA.; Brohl AS

Subjects: Ipilimumab*/Ipilimumab*/Ipilimumab*/administration & dosage ; Ipilimumab*/Ipilimumab*/Ipilimumab*/adverse effects ; Ipilimumab*/Ipilimumab*/Ipilimumab*/therapeutic use

• Source: Cancer medicine [Cancer Med] 2024 Jul; Vol. 13 (14), pp. e7464.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.

• Authors : Brandon Lu¹; Wei Fang Dai^2,3; Croxford, Ruth⁴

• Source: Cancer Medicine. May2023, Vol. 12 Issue 10, p11451-11461. 11p.

تفاصيل العنوان

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.

• Authors : Kato K; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Doki Y

Subjects: Ipilimumab*/Ipilimumab*/Ipilimumab*/administration & dosage ; Ipilimumab*/Ipilimumab*/Ipilimumab*/therapeutic use ; Ipilimumab*/Ipilimumab*/Ipilimumab*/adverse effects

• Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7235.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

• Authors : Kazuyuki Numakura; Yuya Sekine; Shingo Hatakeyama

Subjects: nivolumab; survival rate; Male

• Source: Cancer MedCancer Medicine, Vol 12, Iss 16, Pp 16837-16845 (2023)

تفاصيل العنوان

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis

• Authors : Yuanquan Yang; Sherry V. Mori; Mingjia Li

Subjects: nivolumab; renal cell carcinoma; salvage treatment

• Source: Cancer MedCancer Medicine, Vol 11, Iss 7, Pp 1669-1677 (2022)

تفاصيل العنوان

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma

• Authors : Mia Salans; Patrick Travis Courtney; Anthony Yip

Subjects: Male; Cost-Benefit Analysis; Neoplasms. Tumors. Oncology. Including cancer and carcinogens

• Source: Cancer MedCancer Medicine, Vol 10, Iss 19, Pp 6618-6626 (2021)

تفاصيل العنوان

Correction to 'Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (CheckMate 648): 29‐Month Follow‐Up From a Randomized, Open‐Label, Phase III Trial'

Subjects: Correction

• Source: Cancer Med

تفاصيل العنوان